U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C62H88N13O14P.Co.HO
Molecular Weight 1346.3575
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROXOCOBALAMIN

SMILES

Cc1cc2c(cc1C)[n+](c[nH]2)[C@]3([H])[C@@]([H])([C@@]([H])([C@@]([H])(CO)O3)OP(=O)(O)O[C@]([H])(C)CN=C(CC[C@]4(C)[C@@]([H])(CC(=N)[O-])[C@]5([H])[C@@]6(C)[C@@](C)(CC(=N)O)[C@]([H])(CCC(=N)[O-])C(=C(C)C7=NC(=CC8=NC(=C(C)C4=N5)[C@@]([H])(CCC(=N)[O-])C8(C)C)[C@@]([H])(CCC(=N)[O-])[C@]7(C)CC(=N)O)N6)O)O.[Co+3].O

InChI

InChIKey=YOZNUFWCRFCGIH-WZHZPDAFSA-K
InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1

HIDE SMILES / InChI
Hydroxocobalamin (also hydroxycobalamin, OHCbl) is a natural form, or vitamer, of vitamin B12. It is a member of the cobalamin family of compounds. Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3’-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole. The drug substance is the hydroxylated active form of vitamin B12 and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring. It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide poisoning may develop rapidly within minutes, depending on the route and extent of cyanide exposure. The action of Cyanokit is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine.

CNS Activity

Curator's Comment:: Acetic acid was shown to cross the blood brain barrier in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CYANOKIT

Approved Use

Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3)

Launch Date

1.16614077E12
Curative
VOSOL

Approved Use

For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial.

Launch Date

-3.03868805E11
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4511.6 μM × h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.2 h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, intramuscular
Dose: 20 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
20 g single, intravenous
Highest studied dose
Dose: 20 g
Route: intravenous
Route: single
Dose: 20 g
Sources:
unhealthy, 26.9 years
n = 1
Health Status: unhealthy
Age Group: 26.9 years
Sex: M
Population Size: 1
Sources:
5 g single, intravenous
Overdose
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Condition: cyanide toxicity
Age Group: 3 years
Sex: F
Population Size: 1
Sources:
5 g single, intravenous
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 62 years
n = 1
Health Status: unhealthy
Condition: Vasoplegic Syndrome
Age Group: 62 years
Sex: M
Population Size: 1
Sources:
2000 ug 2 times / day multiple, oral
Dose: 2000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 2000 ug, 2 times / day
Sources:
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: pernicious anaemia
Age Group: adult
Population Size: 8
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury.
1984 Oct
Enzymes of vitamin B6 degradation. Purification and properties of two N-acetylamidohydrolases.
1985 Feb 25
Bacterial organomercurial lyase: overproduction, isolation, and characterization.
1986 Nov 4
Characterization of two novel propachlor degradation pathways in two species of soil bacteria.
1999 Feb
Subcellular localization of Rab17 by cryo-immunogold electron microscopy in epithelial cells grown on polycarbonate filters.
2001
Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang).
2001 Feb
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy.
2001 Feb
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.
2001 Feb
Videographic assessment of the embolic characteristics of three polymeric compounds: ethylene vinyl alcohol, cellulose acetate, and liquid urethane.
2001 Feb
Bacterial release of arsenic ions and organoarsenic compounds from soil contaminated by chemical warfare agents.
2001 Feb
Physiological responses to mixing in large scale bioreactors.
2001 Feb 13
Arginine catabolism by Thermanaerovibrio acidaminovorans.
2001 Feb 20
Cation-exchange purification of mutagenized bovine beta-casein expressed in transgenic mouse milk: its putative Asn68-linked glycan is heterogeneous.
2001 Jan
Measurement of myocardial blood flow with PET using 1-11C-acetate.
2001 Jan
Purification and characterization of a cellulase from the ruminal fungus Orpinomyces joyonii cloned in Escherichia coli.
2001 Jan
Three types of K(+) currents in murine osteocyte-like cells (MLO-Y4).
2001 Jan
Analgesic activity of Peperomia pellucida aerial parts in mice.
2001 Jan
Novel test and its automation for the determination of erythrocyte acetylcholinesterase and its application to organophosphate exposure.
2001 Jan
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
2001 Jan
Differential effects of lead and zinc on inhibitory avoidance learning in mice.
2001 Jan
Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.
2001 Jan
Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
2001 Jan
Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy.
2001 Jan
Inactivation of infective larvae of Angiostrongylus costaricensis with short time incubations in 1.5% bleach solution, vinegar or saturated cooking salt solution.
2001 Jan 15
Energetics of growth and penicillin production in a high-producing strain of Penicillium chrysogenum.
2001 Jan 20
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores.
2001 Jan 22
Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia.
2001 Jan 22
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers.
2001 Jan 5
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis.
2001 Jan 5
Improvement in bioreactor productivities using free radicals: HOCl-induced overproduction of xanthan gum from Xanthomonas campestris and its mechanism.
2001 Jan 5
Succinic acid production with reduced by-product formation in the fermentation of Anaerobiospirillum succiniciproducens using glycerol as a carbon source.
2001 Jan 5
p300 does not require its acetylase activity to stimulate p73 function.
2001 Jan 5
Metabolic fate of [14C]-ethanol into endothelial cell phospholipids including platelet-activating factor, sphingomyelin and phosphatidylethanol.
2001 Jan-Feb
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture.
2001 Jan-Feb
Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8.
2001 Jan-Feb
Production of ethanol and xylitol from corn cobs by yeasts.
2001 Mar
Measurement of low picomolar levels of triamcinolone acetonide in human bronchoalveolar lavage fluid by gas chromatography-electron-capture negative-ion mass spectrometry.
2001 Mar 1
Characterization of bioreaction processes: aerobic Escherichia coli cultures.
2001 Nov 30
Sources of oxygen radicals in brain in acute ammonia intoxication in vivo.
2003 Aug 15
Cobalamin transport proteins and their cell-surface receptors.
2003 Jun 13
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates.
2009 Apr 1
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis.
2010 Jan 22
Patents

Sample Use Guides

To promote continuous contact, insert a wick of cotton saturated with the drug solution (Vosol). Keep the wick in for at least 24 hours and keep it moist by adding 3 to 5 drops of solution every 4 to 6 hours. The wick may be removed after 24 hours but the patient should continue to instill 5 drops of the drug solution 3 or 4 times daily thereafter, for as long as indicated.
Route of Administration: Otic (auricular)
In Vitro Use Guide
Curator's Comment:: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Acetic acid inhibited Saccharomyces cerevisiae growth. The minimum inhibitory concentration (MIC) of acetic acid for yeast growth was 0.6% w/v (100 mM).
Name Type Language
HYDROXOCOBALAMIN
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN   INN  
Official Name English
HYDROXOCOBALAMIN [ORANGE BOOK]
Common Name English
HYDROXOCOBALAMIN [VANDF]
Common Name English
HYDROXOCOBALAMIN [JAN]
Common Name English
HYDROXOCOBALAMIN [USAN]
Common Name English
HYDROXOMIN
Brand Name English
HYDROXOCOBALAMIN [EMA EPAR]
Common Name English
HYDROXOCOBALAMIN [MI]
Common Name English
HYDROXOCOBALAMIN [INN]
Common Name English
COBINAMIDE DIHYDROXIDE DIHYDROGEN PHOSPHATE (ESTER), MONO(INNER SALT), 3'-ESTER WITH 5,6-DIMETHYL-1-.ALPHA.-D-RIBOFURANOSYLBENZIMIDAZOLE
Common Name English
ALPHAREDISOL
Brand Name English
HYDROXYCOBALAMIN
Common Name English
HYDROXOCOBALAMIN [MART.]
Common Name English
HYDROXOCOBALAMINUM ANHYDROUS [WHO-IP LATIN]
Common Name English
HYDROXOCOBALAMIN [HSDB]
Common Name English
HYDROXOCOBALAMINE
Common Name English
HYDROXOCOBALAMIN [WHO-DD]
Common Name English
COBINAMIDE, DIHYDROXIDE, DIHYDROGEN PHOSPHATE (ESTER), MONO(INNER SALT), 3'-ESTER WITH 5,6-DIMETHYL-1-.ALPHA.-D-RIBOFURANOSYL-1H-BENZIMIDAZOLE
Common Name English
CYANOKIT
Brand Name English
HYDROXOCOBALAMIN ANHYDROUS [WHO-IP]
Common Name English
HYDROXOCOBALAMIN [USP]
Common Name English
Classification Tree Code System Code
WHO-ATC B03BA03
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
LOINC 55883-3
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
DSLD 3479 (Number of products:24)
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
WHO-VATC QB03BA03
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
NCI_THESAURUS C26017
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
WHO-ATC V03AB33
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
WHO-VATC QV03AB33
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
FDA ORPHAN DRUG 9585
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
NDF-RT N0000175429
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
EMA ASSESSMENT REPORTS CYANOKIT (AUTHORIZED: POISONING)
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
LOINC 55882-5
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
LOINC 55884-1
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 10.1
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
LOINC 2440-6
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
WHO-ATC B03BA53
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
LIVERTOX 488
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
LOINC 55885-8
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
LOINC 55881-7
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
FDA ORPHAN DRUG 177403
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
FDA ORPHAN DRUG 137600
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
Code System Code Type Description
HSDB
3342
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
NCI_THESAURUS
C65868
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
RXCUI
5514
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M6116
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY Merck Index
PUBCHEM
44475014
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
MESH
D006879
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROXOCOBALAMIN
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY Description: Dark red crystals or a red, crystalline powder; odourless. Solubility: Sparingly soluble in water and ethanol (~750 g/l) TS; practically insoluble in acetone R. Category: Antianaemia drug. Storage: Hydroxocobalamin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and 8?C.Labelling: The designation on the container should state whether the substance is in the anhydrous or hydrated form. Additional information: In aqueous solution, Hydroxocobalamin exists as hydroxocobamide in equilibrium with the hydrated ionic form. The anhydrous form of Hydroxocobalamin is very hygroscopic. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.
DRUG CENTRAL
4309
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
PRIMARY
FDA UNII
Q40X8H422O
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
WIKIPEDIA
HYDROXOCOBALAMIN
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
EVMPD
SUB08074MIG
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
PRIMARY
ECHA (EC/EINECS)
236-533-2
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
DRUG BANK
DB00200
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
PRIMARY
CAS
13422-51-0
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
PRIMARY
INN
1043
Created by admin on Fri Jun 25 23:20:42 UTC 2021 , Edited by admin on Fri Jun 25 23:20:42 UTC 2021
PRIMARY
ChEMBL
CHEMBL2103737
Created by admin on Fri Jun 25 23:20:41 UTC 2021 , Edited by admin on Fri Jun 25 23:20:41 UTC 2021
PRIMARY